PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EBS vs. NVDA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EBS and NVDA is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

EBS vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Emergent BioSolutions Inc. (EBS) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
8.42%
13.83%
EBS
NVDA

Key characteristics

Sharpe Ratio

EBS:

3.38

NVDA:

1.55

Sortino Ratio

EBS:

3.81

NVDA:

2.11

Omega Ratio

EBS:

1.52

NVDA:

1.27

Calmar Ratio

EBS:

5.54

NVDA:

3.26

Martin Ratio

EBS:

17.34

NVDA:

9.28

Ulcer Index

EBS:

31.59%

NVDA:

9.52%

Daily Std Dev

EBS:

162.42%

NVDA:

56.74%

Max Drawdown

EBS:

-98.89%

NVDA:

-89.73%

Current Drawdown

EBS:

-92.08%

NVDA:

-20.60%

Fundamentals

Market Cap

EBS:

$540.22M

NVDA:

$2.91T

EPS

EBS:

-$11.22

NVDA:

$2.53

PEG Ratio

EBS:

1.55

NVDA:

0.84

Total Revenue (TTM)

EBS:

$848.90M

NVDA:

$91.17B

Gross Profit (TTM)

EBS:

$249.10M

NVDA:

$69.14B

EBITDA (TTM)

EBS:

$25.50M

NVDA:

$60.32B

Returns By Period

In the year-to-date period, EBS achieves a 11.82% return, which is significantly higher than NVDA's -11.65% return. Over the past 10 years, EBS has underperformed NVDA with an annualized return of -8.05%, while NVDA has yielded a comparatively higher 73.42% annualized return.


EBS

YTD

11.82%

1M

3.59%

6M

8.42%

1Y

598.69%

5Y*

-29.74%

10Y*

-8.05%

NVDA

YTD

-11.65%

1M

-17.87%

6M

13.83%

1Y

71.17%

5Y*

80.13%

10Y*

73.42%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EBS vs. NVDA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EBS
The Risk-Adjusted Performance Rank of EBS is 9797
Overall Rank
The Sharpe Ratio Rank of EBS is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of EBS is 9696
Sortino Ratio Rank
The Omega Ratio Rank of EBS is 9595
Omega Ratio Rank
The Calmar Ratio Rank of EBS is 9898
Calmar Ratio Rank
The Martin Ratio Rank of EBS is 9797
Martin Ratio Rank

NVDA
The Risk-Adjusted Performance Rank of NVDA is 8787
Overall Rank
The Sharpe Ratio Rank of NVDA is 8888
Sharpe Ratio Rank
The Sortino Ratio Rank of NVDA is 8282
Sortino Ratio Rank
The Omega Ratio Rank of NVDA is 8080
Omega Ratio Rank
The Calmar Ratio Rank of NVDA is 9595
Calmar Ratio Rank
The Martin Ratio Rank of NVDA is 9191
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EBS vs. NVDA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EBS, currently valued at 3.38, compared to the broader market-2.000.002.004.003.381.55
The chart of Sortino ratio for EBS, currently valued at 3.81, compared to the broader market-4.00-2.000.002.004.003.812.11
The chart of Omega ratio for EBS, currently valued at 1.52, compared to the broader market0.501.001.502.001.521.27
The chart of Calmar ratio for EBS, currently valued at 5.54, compared to the broader market0.002.004.006.005.543.26
The chart of Martin ratio for EBS, currently valued at 17.34, compared to the broader market-10.000.0010.0020.0017.349.28
EBS
NVDA

The current EBS Sharpe Ratio is 3.38, which is higher than the NVDA Sharpe Ratio of 1.55. The chart below compares the historical Sharpe Ratios of EBS and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
3.38
1.55
EBS
NVDA

Dividends

EBS vs. NVDA - Dividend Comparison

EBS has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.


TTM20242023202220212020201920182017201620152014
EBS
Emergent BioSolutions Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%5.65%0.00%0.00%
NVDA
NVIDIA Corporation
0.02%0.02%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%1.70%

Drawdowns

EBS vs. NVDA - Drawdown Comparison

The maximum EBS drawdown since its inception was -98.89%, which is greater than NVDA's maximum drawdown of -89.73%. Use the drawdown chart below to compare losses from any high point for EBS and NVDA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-92.08%
-20.60%
EBS
NVDA

Volatility

EBS vs. NVDA - Volatility Comparison

The current volatility for Emergent BioSolutions Inc. (EBS) is 15.33%, while NVIDIA Corporation (NVDA) has a volatility of 25.00%. This indicates that EBS experiences smaller price fluctuations and is considered to be less risky than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
15.33%
25.00%
EBS
NVDA

Financials

EBS vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between Emergent BioSolutions Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab